Clinical Focus

  • Electroshock Therapy
  • NeuroPsychiatry
  • Refractory Affective Disorders
  • Psychiatry

Academic Appointments

  • Professor - University Medical Line, Psychiatry and Behavioral Sciences
  • Professor - University Medical Line (By courtesy), Neurology

Professional Education

  • Board Certification: United Council for Neurologic Subspecialties, Behavioral Neurology and Neuropsychiatry (2012)
  • Residency: Tufts Medical Center Internal Medicine Residency (1979) MA
  • Internship: St Vincent's Hospital (Closed 12/2010) (1975) NY
  • Medical Education: SUNY Downstate School of Medicine Registrar (1974) NY
  • Residency: Stanford University Psychiatry and Behavioral Sciences (1987) CA
  • Fellowship: Stanford University Psychiatry and Behavioral Sciences (1986) CA
  • Residency: Stanford University Psychiatry and Behavioral Sciences (1986) CA
  • Board Certification: American Board of Psychiatry and Neurology, Psychiatry (1988)
  • Board Certification: American Board of Internal Medicine, Internal Medicine (1981)
  • Fellowship: University of Vermont Medical Center (1981) VT

Contact

  • Academic
    jbarry@stanford.edu
    University - Faculty Department: Psych/General Psychiatry and Psychology (Adult) Position: Professor-Univ Med Line
  • Clinical (Primary)  Psychiatry Department 401 Quarry Rd Rm 2303 MC 5723 Stanford, CA 94305 (650) 724-9900 (fax)

Additional Clinical Info

Additional Info

  • Mail Code: 5723

Links

Clinical Trials

  • Memantine Augmentation in Obsessive-Compulsive Disorder Not Recruiting

    The purpose of this study is to determine whether memantine is safe and effective when used as an augmentation to standard treatment for Obsessive-Compulsive Disorder (OCD).

    Stanford is currently not accepting patients for this trial. For more information, please contact Nona Gamel, (650) 723 - 8601.

    View full details

  • Mild Depression 2 Week Observational Study Not Recruiting

    The purpose of this study is to assess whether the dysphoric-like depressive characteristics observed in people with epilepsy are unique to this patient population in comparison to three control groups: Mild Depression (enrolled at Stanford University), Migraine Headaches (enrolled at Long Island Jewish Medical Center), and Multiple Sclerosis (enrolled at Rush University Medical Center).

    Stanford is currently not accepting patients for this trial. For more information, please contact Jessica Hawkins, (650) 723 - 8323.

    View full details

2023-24 Courses

All Publications

  • Depressive and anxiety disorders in epilepsy: Do they differ in their potential to worsen common antiepileptic drug-related adverse events? EPILEPSIA Kanner, A. M., Barry, J. J., Gilliam, F., Hermann, B., Meador, K. J. 2012; 53 (6): 1104-1108

    Abstract

    To compare the effect of anxiety disorders, major depressive episodes (MDEs), and subsyndromic depressive episodes (SSDEs) on antiepileptic drug (AED)-related adverse events (AEs) in persons with epilepsy (PWE).The study included 188 consecutive PWE from five U.S. outpatient epilepsy clinics, all of whom underwent structured interviews (SCID) to identify current and past mood disorders and other current Axis I psychiatric diagnoses according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria. A diagnosis of SSDE was made in patients with total Beck Depression Inventory-II (BDI-II) scores >12 or the Centers of Epidemiologic Studies-Depression (CES-D) > 16 (in the absence of any DSM diagnosis of mood disorder. The presence and severity of AEs was measured with the Adverse Event Profile (AEP).Compared to asymptomatic patients (n = 103), the AEP scores of patients with SSDE (n = 26), MDE only (n = 10), anxiety disorders only (n = 21), or mixed MDE/anxiety disorders (n = 28) were significantly higher, suggesting more severe AED-related AEs. Univariate analyses revealed that having persistent seizures in the last 6 months and taking antidepressants was associated with more severe AEs. Post hoc analyses, however, showed that these differences were accounted for by the presence of a depressive and/or anxiety disorders.Depressive and anxiety disorders worsen AED-related AEs even when presenting as a subsyndromic type. These data suggest that the presence of psychiatric comorbidities must be considered in their interpretation, both in clinical practice and AED drug trials.

    View details for DOI 10.1111/j.1528-1167.2012.03488.x

    View details for Web of Science ID 000304715900023

    View details for PubMedID 22554067